

SLR:slr 3/12/04 261610.doc  
PATENT

Attorney Reference Number 6395-62261  
Application Number 10/072,722

### Claims

1. (currently amended) A composition comprising an isolated, adult *Taenia solium* excretory/secretory polypeptide, wherein the polypeptide has a molecular weight of approximately 33 kDa, 38 kDa, or 42 kDa, as determined by SDS-PAGE analysis.

2. (cancelled)

2 ~~3~~. (previously presented) The composition of Claim 1 wherein the polypeptide has a molecular weight of approximately 32.7 kDa, 37.8 kDa, or 42.1 kDa, as determined by SDS-PAGE analysis.

3 ~~4~~. (previously presented) The composition of Claim 1 wherein the polypeptide is a mixture of two or more isolated, adult *Taenia solium* excretory/secretory polypeptides having molecular weights of approximately 33 kDa, 38 kDa, or 42 kDa, as determined by SDS-PAGE analysis.

4 ~~5~~. (previously presented) The composition of Claim 1 wherein the polypeptide is a mixture of two or more isolated, adult *Taenia solium* excretory/secretory polypeptides having molecular weights of approximately 32.7 kDa, 37.8 kDa, or 42.1 kDa, as determined by SDS-PAGE analysis.

5 ~~6~~. (previously presented) The composition of Claim 1 wherein the polypeptide is a mixture of three isolated, adult *Taenia solium* excretory/secretory polypeptides having molecular weights of approximately 33 kDa, 38 kDa, and 42 kDa, as determined by SDS-PAGE analysis.

6 ~~7~~. (previously presented) The composition of Claim 1 wherein the polypeptide is a mixture of three isolated, adult *Taenia solium* excretory/secretory polypeptides having molecular weights of approximately 32.7 kDa, 37.8 kDa, and 42.1 kDa, as determined by SDS-PAGE analysis.

Claims 8-20. (canceled)

7 ~~21~~. (original) The composition of claim 1, wherein the polypeptide is immobilized.

Page 2 of 4

SLR:slr 3/12/04 261610.doc  
PATENT

Attorney Reference Number 6395-62261  
Application Number 10/072,722

8 ~~22~~. (original) The composition of claim 21, wherein the polypeptide is immobilized to a solid phase bead or particle.

9 ~~23~~. (previously presented) The composition of claim 1, wherein the polypeptide is labeled.

10 ~~24~~. (original) The composition of claim 23, wherein the label is a fluorescent molecule, a luminescent molecule, a radiolabel, a chromogenic substance, or an enzyme.

11 ~~25~~. (previously presented) A kit comprising the composition of claim 1, wherein the composition is in a vessel or on a solid phase.

12 ~~26~~. (original) A kit comprising the composition of claim 1 and instructions for using the kit.

13 ~~27~~. (original) A kit comprising the composition of claim 1, wherein the composition in lyophilized.